MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna Inc (MRNA) is not currently a strong buy for a beginner, long-term investor. While there are positive developments such as the unanimous FDA advisory panel support for its flu vaccine and recent congressional purchase activity, the stock's overbought technical indicators, hedge fund selling, and mixed analyst ratings with low price targets suggest caution. The investor's impatience and unwillingness to wait for optimal entry points make this stock less suitable at the current price level.
The technical indicators suggest a bullish trend with MACD above 0 and expanding, and moving averages showing SMA_5 > SMA_20 > SMA_200. However, the RSI_6 at 88.652 indicates the stock is overbought, signaling potential short-term downside risk. Key resistance levels are at R1: 63.634 and R2: 68.906, while support levels are at S1: 46.566 and S2: 41.294.
The FDA advisory panel's unanimous 9-0 vote in favor of Moderna's mRNA flu vaccine for adults aged 50-
Congressional purchase activity with a median transaction amount of $0.8M, indicating positive sentiment from influential figures.
Bullish technical indicators such as MACD and moving averages.
Hedge funds are selling the stock, with a 437.15% increase in selling activity over the last quarter.
Analysts maintain mixed ratings with low price targets, ranging from $32 to $50, reflecting limited confidence in near-term upside.
RSI indicates the stock is overbought, suggesting potential for a pullback.
Financial data for the latest quarter is unavailable, but analysts note better-than-expected Q1 results driven by international markets. Growth prospects depend on uptake of oncology data and pipeline updates.
Analysts have mixed ratings on Moderna, with most maintaining Neutral, Hold, or Underperform ratings. Price targets range from $32 to $50, indicating limited upside potential. While there is optimism surrounding the flu vaccine approval, significant revenue contributions are not expected until 2027.
